A
web-based Atlas of Patient-Derived Xenografts
of cancer patients:A resource of MURAL PDX data
PDX model details
| PDX ID | 435.31A |
|---|---|
| Host Strain(and Source) | NSG Source: Monash University |
| Host Strain Immune system Humanized | NO |
| Host Type | Testosterone supplemented |
| Graft Site | Subcutaneous |
| Current Generation (* indicates number of generations grown in Castrate host) |
4 |
| Average PDX Generation Time (days +/- SEM) | 53 ± 3 |
| Tumor preparation | Tumor solid |
| Tumor Characterization Technology | Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq |
| Tumor confirmed not to be of Mouse/EBV origin | Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC |
| Passage QA performed | Routine QA every 2-3 passages |
| Associated meta data | |
| PDX model availability | Yes (fixed, frozen) |
| Governance restriction for distribution | Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements |
| Pubmed ID | 34413304 |
| Markers | 435.31A |
|---|---|
| AR | N |
| PSA | N |
| PSMA | N |
| NE | Y |
| ERG | N |
No information in CNV Table
Clinical Information
| Sample Number | 435.31A |
|---|---|
| Sample Site | Right thalamus |
| Sample source | Autopsy |
| Pathology Tumor Diagnosis | None |
| Gleason Score | None |
| Primary Gleason Score | None |
| Secondary Gleason Score | None |
| Tertiary Gleason Score | None |
| ISUP Grade Group | |
| Tumor Grade | |
| D'Amico Risk Classification | |
| Tumor Volume (in cc) | 0.0 |
| Treatment Prior to Specimen Collection | ADT, carboplatin plus etoposide |
Patient Information
| Patient Number | 435 |
|---|---|
| Sex | Male |
| Diagnosis | Prostate Cancer |
| PSA at diagnosis (ng/mL) | 16.2 |
| Consent to share data | |
| Patient Tumor Collection (Current Model) | |
|---|---|
| Tumour sample ID | 435.31A |
| Patient Age (binned in 5 year age groups) | 65-74 |
No information in Mutation Table
No information in Drug dosing Table